lipegfilgrastim 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
granulocyte colony stimulating factor (G-CSF) type substances 4991 1117844-87-7

Description:

MoleculeDescription

Synonyms:

  • lipegfilgrastim
  • lonquex
  • XM22
A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.30 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 25, 2013 EMA Sicor Biotech UAB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 90.68 45.40 43 1020 97624 50506437
Post-traumatic pain 61.49 45.40 10 1053 366 50603695
Thrombocytopenia 47.94 45.40 31 1032 127642 50476419

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Testicular germ cell cancer metastatic 65.91 43.45 9 975 57 29573486
General physical health deterioration 57.52 43.45 38 946 102819 29470724
Seminoma 54.88 43.45 9 975 216 29573327
Rectal polyp 46.40 43.45 9 975 569 29572974
Thrombocytopenia 43.97 43.45 36 948 134787 29438756

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 90.92 40.39 68 2071 223733 64272860
Neutropenia 82.46 40.39 66 2073 239558 64257035
Leukopenia 72.96 40.39 44 2095 101198 64395395
Febrile neutropenia 71.63 40.39 55 2084 187602 64308991
General physical health deterioration 69.59 40.39 56 2083 204369 64292224
Testicular germ cell cancer metastatic 66.05 40.39 9 2130 56 64496537
Post-traumatic pain 56.19 40.39 10 2129 394 64496199
Seminoma 56.17 40.39 9 2130 186 64496407
Polyneuropathy 48.98 40.39 20 2119 19874 64476719
Lymphopenia 44.08 40.39 20 2119 25637 64470956
Neuropathy peripheral 41.59 40.39 33 2106 117492 64379101

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AA14 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Colony stimulating factors

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced neutropenia indication 425229001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Granulocyte colony-stimulating factor receptor Membrane receptor ACTIVATOR DRUG LABEL DRUG LABEL

External reference:

IDSource
4AWF0N6QV3 UNII
D10242 KEGG_DRUG
C3640212 UMLSCUI
CHEMBL4594230 ChEMBL_ID
77910626 PUBCHEM_CID
DB13200 DRUGBANK_ID
9342 INN_ID
C455861 MESH_SUPPLEMENTAL_RECORD_UI
1440046 RXNORM
710282003 SNOMEDCT_US
015533 NDDF

Pharmaceutical products:

None